ripostatin b profile

ripostatin B: an inhibitor of eubacterial RNA polymerase; isolated from Sorangium cellulosum; a macrocyclic lactone carbonic acid; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10391134
MeSH ID	M0254131

Synonyms (2)

Synonym
ripostatin b
2-[(3e,6e,9e,12r,14s)-12-hydroxy-14-[(e,2r)-2-hydroxy-5-methyl-7-phenylhept-5-enyl]-10-methyl-2-oxo-1-oxacyclotetradeca-3,6,9-trien-4-yl]acetic acid

Research Excerpts

Overview

Ripostatin B is a polyketide-derived 14-membered macrolide that acts as an inhibitor of bacterial RNA-polymerase. It is mechanistically distinct from rifamycin-derived RNA-Polymerase inhibitors that are used for tuberculosis treatment.

Excerpt	Reference	Relevance
"Ripostatin B is a polyketide-derived 14-membered macrolide that acts as an inhibitor of bacterial RNA-polymerase, but is mechanistically distinct from rifamycin-derived RNA-polymerase inhibitors that are in use for tuberculosis treatment."	( Total Synthesis of Ripostatin B and Structure-Activity Relationship Studies on Ripostatin Analogs. Aínsa, JA; Altmann, KH; Cole, ST; Dedić, D; Glaus, F; Hartkoorn, RC; Kunze, J; Nagaraja, V; Rodrigues, L; Schneider, G; Tare, P, 2018)	1.53

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	0 (0.00)	29.6817
2010's	7 (87.50)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.13 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.32 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.13)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies
fidaxomicin Fidaxomicin: A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.. fidaxomicin : An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.	3.16	1
ripostatin a ripostatin A: an inhibitor of eubacterial RNA polymerase; a macrocyclic lactone carbonic acid; isolated from Sorangium cellulosum; structure given in first source	3.52	2
myxopyronin a myxopyronin A: from Myxococcus fulvus; structure given in first source	3.16	1
corallopyronin a corallopyronin A: structure in first source	3.16	1

ripostatin b

Description